Table 1. Definitions of “high” TMB.
| Study/reference | Technique | Definition of high TMB (method of determination) |
|---|---|---|
| Hellmann et al. 2018 (29) | WES | ≥158 mutations (median) |
| Hellmann et al. 2018 (CheckMate 227) (26) | FoundationOne CDx | ≥10 mutations/Mb (ROC) |
| Rizvi et al. 2018 (30) | MSK-IMPACT | ≥7.4 mutations/Mb (median) |
| Kowanetz et al. 2017 (47) | FoundationOne | ≥13.5 mutations/Mb (75th percentile; first-line treatment) |
| ≥17.1 mutations/Mb (75th percentile; second-line# treatment) | ||
| Chalmers et al. 2017 (31) | FoundationOne CDx | ≥20 mutations/Mb (?¶) |
| Carbone et al. 2017 (CheckMate 026) (27) | WES | ≥243 mutations (?¶) |
| Rizvi et al. 2015 (25) | WES | ≥209 mutations (median) |
¶, no information was provided on how the cut-off value was determined; #, second-line treatment or later. WES, whole exome sequencing; MSK-IMPACT, Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets; ROC, receiver operating characteristics; TMB, tumor mutation burden; CDx, companion diagnostic test.